NCT02968940View on ClinicalTrials.gov

Avelumab With Hypofractionated Radiation Therapy in Adults With Isocitrate Dehydrogenase (IDH) Mutant Glioblastoma

PHASE2CompletedINTERVENTIONAL
Enrollment

6

Participants

Timeline

Start Date

March 17, 2017

Primary Completion Date

August 29, 2019

Study Completion Date

August 29, 2019

Conditions
Glioblastoma
Interventions
BIOLOGICAL

Avelumab

Avelumab 10 mg/kg intravenously (IV) every 2 weeks

RADIATION

Hypofractionated radiation therapy (HFRT)

Hypofractionated radiation therapy to a total dose of 30 Gy, delivered in 6 Gy per fraction for 5 consecutive daily fractions

Trial Locations (4)

10016

Laura & Isaac Perlmutter Cancer Center & NYU Langone Medical Center, New York

90095

University of California, Los Angeles (UCLA), Los Angeles

94143

UCSF Medical Center, San Francisco

02114

Massachusetts General Hospital, Boston

Sponsors

Collaborators (1)

EMD Serono
All Listed Sponsors
collaborator

EMD Serono

INDUSTRY

lead

NYU Langone Health

OTHER

NCT02968940 - Avelumab With Hypofractionated Radiation Therapy in Adults With Isocitrate Dehydrogenase (IDH) Mutant Glioblastoma | Biotech Hunter | Biotech Hunter